Retinal Vein Occlusion Market Size and Share - Growth Analysis Report and Forecast Trends 2026-2030

Retinal Vein Occlusion is a leading cause of visual impairment worldwide, ranking as the second most common retinal vascular disorder after diabetic retinopathy. The condition occurs when a thrombus forms in the retinal venous circulation, leading to macular edema, retinal hemorrhage, and potential permanent vision loss if untreated. The global market encompasses pharmacologic therapies, primarily anti-VEGF agents and corticosteroids, as well as associated diagnostic, surgical, and monitoring services required for long-term disease management.

• •RVO affects an estimated 16 million people globally, with prevalence rising sharply in populations over 50 years of age.
• •The condition represents a major driver of healthcare expenditure due to its chronic nature requiring repeated intravitreal injections.
• •Central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO) constitute the two primary clinical subtypes, each with distinct treatment protocols.

The primary engine of market expansion is the growing global burden of RVO, fueled by aging demographics and the rising worldwide prevalence of hypertension, diabetes, glaucoma, and cardiovascular disease, all established risk factors for the condition. Advances in intravitreal drug delivery have transformed RVO from a largely untreatable condition into a manageable chronic disease, dramatically increasing the patient pool receiving therapy and the frequency of retreatment visits.

• •Anti-VEGF therapies, which form the backbone of RVO treatment, are projected within the broader ophthalmology anti-VEGF segment to reach $17.99 billion by 2030 at an 8.2% CAGR, driven by RVO, diabetic retinopathy, and neovascular AMD.
• •Improved screening, diagnostic imaging (OCT), and greater physician awareness have increased detection rates and earlier intervention.
• •The socioeconomic cost of vision loss from RVO, including lost productivity and long-term disability, continues to drive healthcare system prioritization of treatment access.

The market is segmented primarily by drug class, anti-VEGF agents, corticosteroid implants, and ancillary therapies, and by geography, with North America and Europe currently commanding the largest revenue shares due to established healthcare infrastructure and high treatment adoption. The Asia-Pacific region is emerging as the fastest-growing market, reflecting rising disease prevalence, improving ophthalmology care access, and growing affordability of biologic therapies in countries including China, India, and Japan.

• •North America leads in market revenue, supported by high per-capita healthcare spending, favorable reimbursement policies, and strong pharmaceutical marketing infrastructure.
• •Europe represents the second-largest segment, with Western Europe driving volume and Eastern Europe gradually expanding access to intravitreal therapies.
• •Latin America, the Middle East, and Africa present untapped growth potential as healthcare systems invest in retinal disease management capacity.

What are the recent trends and outlook?

The RVO market is poised for continued expansion through 2034, with the projected 7.15% CAGR reflecting both increasing patient volumes and the gradual adoption of next-generation therapies. Key trends include the commercialization of anti-VEGF biosimilars, development of sustained-release and port-delivery drug systems to reduce injection burden, and exploration of gene therapy and RNA-based treatments targeting VEGF pathways. These innovations aim to address patient adherence challenges and reduce the long-term cost of chronic intravitreal injection regimens.

• •The anti-VEGF biosimilar pipeline is expected to gain regulatory momentum through the late 2020s, potentially creating cost savings and expanding treatment access in price-sensitive markets.
• •Sustained-release corticosteroid and drug-eluting implant technologies are advancing through clinical trials, with the potential to shift part of the market away from repeated injection therapies.
• •Combination therapies, personalized treatment protocols based on biomarkers, and novel mechanisms of action (e.g., gene therapy, DMEK-targeted interventions) represent the longer-term pipeline opportunities beyond the current anti-VEGF-centric standard of care.